Table 1

Demographic, clinical, and laboratory information of patients
Subject
 Sex
 Age (years)
 Medications
 CRP (mg/l)
 ESR (mm/hour)
RA Patients




     RA-1aa
 Male
 65
 None
 4.14b
 9
     RA-1b
 Male
 65
 MTX
 11.8
 18
     RA-2
 Female
 33
 Etanercept, naproxen
 25.7
 18
     RA-3
 Female
 43
 Etanercept
 No data
 No data
     RA-4
 Female
 45
 None
 98.4
 84
     RA-5
 Female
 55
 MTX
 4.8
 26
     RA-6
 Female
 73
 None
 2.1
 30
     RA-7
 Female
 51
 Hydroxychloroquine, MTX, prednisone
 No data
 15
     RA-8
 Male
 61
 Prednisone, MTX, hydroxychloroquine, sulfasalazine
 No data
 1
     RA-9
 Male
 46
 Methylprednisolone, MTX, etanercept
 2
 9
     RA-10
 Female
 32
 Leflunomide
 94.2
 63
     RA-11
 Female
 50
 Etanercept, MTX
 No data
 No data
     RA-12
 Male
 67
 MTX, celecoxib, prednisone
 0.6
 11
     RA-13
 Female
 55
 MTX
 No data
 17
     RA-14
 Female
 33
 Hydroxychloroquine, ibuprofen
 2.8
 7
     RA-15
 Female
 55
 None
 168.2
 88
     RA-16
 Female
 56
 Prednisone, minocycline
 No data
 No data
Disease control individuals




     SLE1
 Female
 36
 Hydroxychloroquine, prednisone, mycophenolate mofetil

     SjS1
 Female
 30
 Hydroxychloroquine, mycophenolate mofetil

     SjS2
 Male
 21
 Hydroxychloroquine

     SSc1
 Female
 57
 Cyclosporine, hydroxychloroquine, prednisone, mycophenolate mofetil

aSample collected from RA-1 before and after MTX treatment. bNormal value less than 0.8. The normal CRP is <4.9 mg/l, and the normal ESR is <20 mm/hour for females and <10 mm/hour for males. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SjS, Sjögren's syndrome; SSc, scleroderma.

Pauley et al. Arthritis Research & Therapy 2008 10:R101   doi:10.1186/ar2493

Open Data